PeptideJournal
Peptide Profiles23 min read

IGF-1 DES: Truncated IGF Variant Profile

IGF-1 DES (Des(1-3)IGF-1) is a naturally occurring, truncated variant of insulin-like growth factor-1 that has garnered research attention for its unique pharmacological properties.

IGF-1 DES (Des(1-3)IGF-1) is a naturally occurring, truncated variant of insulin-like growth factor-1 that has garnered research attention for its unique pharmacological properties. Missing the first three amino acids from its N-terminus, this 67-amino acid peptide demonstrates approximately 10-fold greater potency than native IGF-1 at receptor sites, primarily because it exhibits minimal binding to IGF binding proteins that normally sequester and regulate IGF-1 activity. With a half-life measured in minutes rather than hours, IGF-1 DES operates through highly localized, transient effects that distinguish it from longer-acting IGF-1 analogs.

Research interest in IGF-1 DES centers on its potential for targeted tissue applications. The peptide has been isolated from bovine colostrum, human brain tissue, and porcine uterus, suggesting it may serve physiological roles in localized growth signaling. Its structure — lacking the glutamic acid at position 3 that mediates binding protein interactions — makes it a valuable research tool for studying IGF-1 receptor signaling without the confounding effects of binding protein sequestration.

Table of Contents

Quick Facts

PropertyDetails
Peptide ClassTruncated IGF-1 analog
Structure67 amino acids (missing N-terminal Gly-Pro-Glu)
Half-Life20-30 minutes
Potency~10× more potent than native IGF-1
IGFBP Binding~1% of native IGF-1 binding affinity
Primary EffectLocalized tissue growth and protein synthesis
Natural OccurrenceFound in colostrum, brain tissue, uterus
Regulatory StatusResearch chemical; prohibited in competitive sports

What Is IGF-1 DES?

IGF-1 DES, formally known as Des(1-3)IGF-1, is a truncated variant of insulin-like growth factor-1 that lacks the first three amino acids (glycine-proline-glutamic acid) at its N-terminus. This structural modification produces a 67-amino acid peptide, compared to the 70 amino acids in native IGF-1. The peptide occurs naturally in several biological contexts and has been isolated from bovine colostrum, human brain tissue, and porcine uterus.

The removal of these three amino acids fundamentally alters how the peptide interacts with its regulatory system. While native IGF-1 circulates bound to IGF binding proteins (IGFBPs) that control its bioavailability and duration of action, IGF-1 DES demonstrates profoundly reduced affinity for these binding proteins — retaining only about 1% of the binding capacity of full-length IGF-1. This characteristic translates to greater receptor availability and higher local potency.

Des(1-3)IGF-1 retains normal affinity for the type 1 IGF receptor (IGF1R), the primary signaling receptor responsible for mediating IGF-1's growth-promoting effects. Research demonstrates that the peptide activates the same downstream signaling pathways as native IGF-1, including the PI3K/Akt/mTOR cascade that drives protein synthesis and cellular growth. The key difference lies in bioavailability: more of the administered peptide reaches receptors rather than being sequestered by binding proteins.

The peptide's extremely short half-life — approximately 20-30 minutes in circulation — means its effects remain highly localized to the site of administration. This pharmacokinetic profile contrasts sharply with native IGF-1 (which has a half-life of several hours) and with long-acting analogs like IGF-1 LR3, which can circulate for 20-30 hours.

Molecular Structure and Properties

The molecular structure of IGF-1 DES directly determines its biological behavior. The peptide's 67-amino acid sequence maintains the core structure necessary for IGF1R binding but eliminates the N-terminal tripeptide that mediates interactions with IGF binding proteins.

Structural Characteristics:

Native IGF-1 contains 70 amino acids arranged in a structure that includes three disulfide bonds connecting specific cysteine residues. These bonds create a compact, stable tertiary structure that resembles insulin — hence the name "insulin-like growth factor." The N-terminal region (amino acids 1-3: Gly-Pro-Glu) contributes to binding affinity for IGFBPs, particularly IGFBP-3, which is the predominant carrier protein for IGF-1 in circulation.

When these three residues are absent, as in Des(1-3)IGF-1, the peptide loses its primary point of contact with binding proteins. Research shows Des(1-3)IGF-1 has several times lower affinity for IGFBP-3 than native IGF-1 and demonstrates greatly reduced binding to all other IGFBPs. This reduced affinity is not absolute — IGFBP-3 at sufficient concentrations can still inhibit Des(1-3)IGF-1 signaling — but the practical effect is that substantially more free peptide remains available to interact with receptors.

Physicochemical Properties:

The molecular weight of IGF-1 DES is approximately 7.4 kDa, slightly less than the 7.6 kDa of full-length IGF-1. The peptide maintains similar solubility characteristics to native IGF-1 and requires acidic pH for optimal stability in solution. Like other peptides in the insulin superfamily, IGF-1 DES is susceptible to proteolytic degradation, which contributes to its short half-life.

The three-dimensional structure remains largely intact despite the N-terminal truncation. The peptide retains the characteristic folding pattern that allows it to fit into the IGF1R binding pocket with normal affinity. Crystallography studies of IGF-1 variants suggest the core receptor-binding domain (roughly amino acids 4-62) remains structurally unchanged in the Des(1-3) variant.

Receptor Binding:

IGF-1 DES binds to the type 1 IGF receptor (IGF1R) with similar affinity to native IGF-1. The IGF1R is a receptor tyrosine kinase that, upon ligand binding, undergoes autophosphorylation and initiates signaling cascades. The peptide shows approximately 10-fold greater potency than native IGF-1 in vivo, not because of increased receptor affinity, but because of increased bioavailability at the receptor site.

The peptide shows minimal cross-reactivity with insulin receptors at physiological concentrations, maintaining specificity for the IGF signaling axis. Some studies indicate Des(1-3)IGF-1 may also interact with type 2 IGF receptors (IGF2R), though this receptor primarily serves a clearance function rather than signaling.

Mechanisms of Action

IGF-1 DES operates through the same fundamental signaling pathways as native IGF-1 but with altered pharmacokinetics that produce distinct temporal and spatial effects.

Receptor Activation and Signaling:

The primary mechanism involves binding to the type 1 IGF receptor (IGF1R), a transmembrane receptor tyrosine kinase expressed on most cell types. Receptor binding triggers autophosphorylation of tyrosine residues on the intracellular domain, creating docking sites for adaptor proteins that initiate downstream signaling.

IGF-1 is one of the most potent natural activators of the Akt signaling pathway. Specifically, IGF1R activation recruits insulin receptor substrate (IRS) proteins, which activate phosphoinositide 3-kinase (PI3K). PI3K converts PIP2 to PIP3 at the cell membrane, recruiting Akt (also called protein kinase B). Once activated, Akt phosphorylates numerous downstream targets that regulate:

  • Protein synthesis: Activation of mTOR (mechanistic target of rapamycin) and downstream effectors including p70S6K and 4E-BP1, which control ribosomal function and translation initiation
  • Protein degradation: Inhibition of FoxO transcription factors that would otherwise promote expression of ubiquitin ligases (atrogin-1 and MuRF1) responsible for protein breakdown
  • Cell survival: Inhibition of pro-apoptotic factors including Bad and caspase-9
  • Glucose metabolism: Translocation of GLUT4 glucose transporters to the cell surface

Research demonstrates that intraperitoneal injection of Des(1-3)IGF-1 in mice produces increased phosphorylation of Akt and p70S6K in skeletal muscle tissue, confirming activation of the mTOR pathway. This signaling cascade drives protein synthesis and is central to muscle hypertrophy.

A parallel pathway involves activation of the RAS-MAPK (mitogen-activated protein kinase) cascade, which regulates cell proliferation and differentiation. This pathway appears particularly important for IGF-1's effects on satellite cells — the muscle stem cells responsible for muscle regeneration and growth.

Reduced Binding Protein Sequestration:

The defining characteristic of IGF-1 DES is its dramatically reduced affinity for IGF binding proteins. All six IGFBPs share approximately 50% homology and bind IGF-1 with affinity similar to or greater than the IGF1R itself. Under normal conditions, more than 99% of circulating IGF-1 is bound to IGFBPs, primarily in a ternary complex with IGFBP-3 and acid-labile subunit (ALS). This binding serves regulatory functions: it extends IGF-1's half-life, creates a circulating reservoir, and restricts IGF-1 access to tissues.

Des(1-3)IGF-1 demonstrates only about 1% of native IGF-1's affinity for IGFBPs while retaining intact affinity for the type 1 IGF receptor. This means substantially more of the administered peptide remains free to interact with receptors. Research quantifies this effect: Des(1-3)IGF-1 shows enhanced potency attributed to increased IGF-1 bioavailability in tissues.

However, the reduced binding protein affinity comes with a trade-off. Without IGFBP stabilization, the peptide has a circulating half-life of only 20-30 minutes compared to several hours for native IGF-1. This shortened duration means effects remain highly localized to the injection site.

Localized Tissue Effects:

The combination of reduced binding protein affinity and short half-life makes IGF-1 DES particularly suited for localized tissue applications. Studies show that localized administration stimulates targeted muscle hypertrophy and fiber remodeling through enhanced anabolic signaling specifically at the injection site.

Research in neural tissue demonstrates that administration of Des-IGF-1 increases field excitatory postsynaptic potential (EPSP) slope in CA1 hippocampal neurons in an AMPA-dependent manner. This finding indicates tissue-specific activity and suggests the peptide can produce localized effects in brain regions without systemic IGF-1 elevation.

Enzymatic Generation:

Interestingly, Des(1-3)IGF-1 can be generated in vivo through enzymatic cleavage of native IGF-1. Research identifies acid proteases in serum that can remove the N-terminal tripeptide, suggesting this conversion may represent a physiological mechanism for increasing local IGF-1 bioavailability. The enzymatic conversion of IGF-1 to Des(1-3)IGF-1 in tissues represents a potential site of growth hormone regulation of IGF-1 action.

Research Applications

IGF-1 DES has been investigated across multiple research domains, from tissue growth and regeneration to metabolic and neurological applications.

Muscle Growth and Protein Synthesis:

The peptide's primary research application involves skeletal muscle anabolism. Multiple studies demonstrate that Des(1-3)IGF-1 promotes muscle protein synthesis through activation of the PI3K/Akt/mTOR pathway. Research shows that IGF-1 increases skeletal muscle protein synthesis via PI3K/Akt/mTOR and PI3K/Akt/GSK3β pathways while simultaneously inhibiting protein degradation.

In rat studies, 14 days of IGF-1 DES treatment produced significant increases in body weight, nitrogen retention, and food conversion efficiency. These effects indicate improved anabolic efficiency — the animals converted dietary protein to tissue mass more effectively than controls.

Research in growth hormone-deficient (lit/lit) mice demonstrated that Des(1-3)IGF-1 is approximately 10-fold more potent than native IGF-1 at stimulating somatic growth. The increased potency is retained when the variant is administered in vivo, with selective anabolic effects particularly evident in gut tissues.

Studies examining phosphorylation status of signaling molecules found increased phosphorylation of Akt and p70S6K in skeletal muscles after Des(1-3)IGF-1 administration, confirming activation of pathways responsible for ribosomal protein synthesis. Notably, research indicates that IGF-1 requires a growth stimulus to induce skeletal muscle hypertrophy. Elevated IGF-1 has hypertrophic effects on skeletal muscle primarily in growth situations such as normal postnatal development or regeneration following injury.

Gastrointestinal Applications:

Des(1-3)IGF-1 has shown particular effectiveness in intestinal growth and recovery. In rats following gut resection (massive small bowel removal), both native IGF-1 and Des(1-3)IGF-1 enhanced growth, but the truncated variant showed superior effects. Animals treated with Des(1-3)IGF-1 stabilized better immediately post-surgery and subsequently gained significantly more weight than vehicle or low-dose IGF-1 groups.

The selective anabolic effects on gastrointestinal tissue may relate to the peptide's bioavailability profile. When administered systemically, more of the free peptide reaches intestinal tissue without being sequestered by binding proteins. This characteristic makes Des(1-3)IGF-1 potentially valuable for research into intestinal adaptation, short bowel syndrome, and gastrointestinal healing.

Renal Disease and Protein Catabolism:

Research in rats with reduced renal mass demonstrates that Des(1-3)IGF-1 may be particularly effective in reducing the rate of muscle protein breakdown associated with renal insufficiency. Chronic kidney disease typically induces a catabolic state characterized by muscle wasting. The peptide's ability to activate Akt and inhibit FoxO-mediated expression of ubiquitin ligases (which tag proteins for degradation) provides a mechanistic basis for this effect.

Studies show that Des(1-3)IGF-1 and native IGF-1 enhance growth in rats with reduced renal mass, though the truncated variant demonstrated greater efficacy at equivalent doses.

Diabetic Complications:

Preclinical research has examined Des(1-3)IGF-1 in diabetic retinopathy. Treatment with the IGF-1 analog normalized type 1 IGF receptor and phospho-Akt immunoreactivity in predegenerative retina of diabetic rats. This finding suggests the peptide can prevent early retinal biochemical abnormalities implicated in the progression of diabetic retinopathy, despite ongoing hyperglycemia.

The mechanism appears to involve restoration of IGF-1 signaling in retinal tissue that becomes IGF-1 resistant in diabetes. By bypassing binding proteins and directly activating receptors, Des(1-3)IGF-1 may overcome some of the signaling deficits characteristic of diabetic tissues.

Neuroprotective Research:

While specific research on Des(1-3)IGF-1 in neural tissue is limited, the peptide's natural occurrence in human brain suggests potential neurological roles. General IGF-1 research demonstrates that exogenously applied IGF-1 reduces neuronal loss and improves motor and cognitive outcomes in animal models of hypoxic-ischemic and traumatic brain injuries.

IGF-1 can cross the blood-brain barrier and performs important functions in the central nervous system, including neurogenesis and neuroprotection, through autocrine, paracrine, or endocrine effects. Research shows IGF-1 might be important in disorders such as ischemic stroke, brain trauma, and Alzheimer's disease by inducing neuroprotective effects against glutamate-mediated excitotoxic signaling.

Des-IGF-1 administration increases field EPSP slope in CA1 hippocampal neurons in an AMPA-dependent manner, demonstrating direct effects on synaptic function. This finding suggests the truncated variant retains native IGF-1's neuromodulatory properties while offering advantages in terms of localized delivery and reduced systemic exposure.

Cell Differentiation:

Research demonstrates that Des(1-3)IGF-1 can promote differentiation of various cell types. Studies show the peptide promotes the differentiation of human colon carcinoma cells, an effect interpreted as mimicking a potential IGF-2 autocrine loop. This research application helps elucidate the role of IGF signaling in cellular maturation and phenotype specification.

Limitations and Considerations:

Most research on Des(1-3)IGF-1 involves animal models or in vitro systems. Human clinical data remains extremely limited, as the peptide has not advanced through formal drug development programs. The peptide's short half-life, while advantageous for localized effects, presents challenges for systemic applications. Its detection in anti-doping analyses indicates it has been used in athletic contexts despite prohibitions, but controlled research in human performance is essentially absent.

IGF-1 DES vs IGF-1 LR3: A Comparison

IGF-1 DES and IGF-1 LR3 represent different approaches to modifying IGF-1 for enhanced bioavailability. Both analogs reduce binding to IGFBPs, but they achieve this through opposite structural modifications that produce distinct pharmacokinetic profiles.

Structural Differences:

IGF-1 DES is a truncated variant missing the first three amino acids at the N-terminus (67 total amino acids). IGF-1 LR3, in contrast, is an extended variant with 83 amino acids — it adds 13 amino acids at the N-terminus and includes an arginine substitution for glutamic acid at position 3. Both modifications reduce IGFBP binding, but through different mechanisms affecting the peptide's N-terminal binding domain.

Half-Life and Duration:

The most clinically significant difference lies in their half-lives:

  • IGF-1 DES: 20-30 minutes
  • IGF-1 LR3: 20-30 hours

This 60-fold difference in half-life fundamentally alters how the peptides behave in biological systems. IGF-1 DES produces rapid, localized effects that dissipate quickly. IGF-1 LR3 circulates systemically for extended periods, producing sustained anabolic effects throughout the body.

Potency and Bioavailability:

IGF-1 DES demonstrates approximately 10-fold greater potency than native IGF-1 at receptor sites, despite equivalent receptor binding affinity. This enhanced potency results from dramatically reduced IGFBP binding — the peptide retains only about 1% of native IGF-1's affinity for binding proteins.

IGF-1 LR3 also shows reduced IGFBP binding, though exact quantification varies across studies. The extended N-terminus and amino acid substitution reduce binding protein affinity while extending circulating half-life through improved stability.

Practical Implications:

These pharmacokinetic differences translate to distinct practical applications:

IGF-1 DES is suited for localized, site-specific effects. The short half-life means systemic exposure remains minimal when the peptide is injected locally. Research applications emphasizing targeted tissue growth — such as localized muscle hypertrophy or intestinal tissue repair — may benefit from this profile. Athletes reportedly inject the peptide directly into muscle groups immediately before training, seeking localized growth with minimal systemic effects.

IGF-1 LR3 excels at systemic muscle growth and recovery. The 20-30 hour half-life means the peptide circulates throughout the body, potentially affecting all tissues expressing IGF1R. This makes site-specific injection unnecessary — the peptide will distribute systemically regardless of injection location. Research applications examining whole-body anabolic effects or conditions requiring sustained IGF-1 elevation favor this profile.

Safety Considerations:

The different half-lives create distinct safety profiles. IGF-1 DES's brief duration means adverse effects, if they occur, resolve quickly. A miscalculated dose or unexpected reaction will clear from the system within hours. IGF-1 LR3's extended circulation means effects — both desired and undesired — persist for days. This extended exposure increases the theoretical risk of sustained hypoglycemia, receptor downregulation, or mitogenic effects.

Neither peptide has been adequately studied in human clinical trials, making definitive safety comparisons impossible. Both are prohibited in competitive sports by the World Anti-Doping Agency.

Research Tool Utility:

As research tools, the peptides serve complementary purposes. IGF-1 DES, with minimal binding protein interaction, provides insights into direct IGF1R signaling without the confounding effects of IGFBP modulation. Its localized effects allow researchers to study tissue-specific responses to IGF-1 signaling.

IGF-1 LR3's extended half-life makes it more practical for sustained dosing experiments where researchers want to maintain elevated IGF-1 signaling over extended periods without frequent dosing.

Safety and Side Effects

Safety data for IGF-1 DES in humans remains limited because the peptide has not undergone formal clinical development or regulatory approval. Available information derives from animal research, in vitro studies, and extrapolation from native IGF-1 pharmacology.

Theoretical Safety Concerns:

Based on the peptide's mechanism of action, several categories of adverse effects warrant consideration:

Hypoglycemia: IGF-1 signaling overlaps with insulin signaling, particularly through the PI3K/Akt pathway that promotes glucose uptake and GLUT4 translocation. While Des(1-3)IGF-1 shows minimal cross-reactivity with insulin receptors, it can lower blood glucose through IGF1R-mediated mechanisms. The short half-life of IGF-1 DES (20-30 minutes) provides a safety advantage here — any hypoglycemic episode would be transient compared to longer-acting analogs.

Proliferative Effects: IGF-1 signaling promotes cell proliferation and inhibits apoptosis, raising theoretical concerns about cancer risk with chronic exposure. IGF-1 has been associated with increased cancer risk in epidemiological studies, though the relationship is complex and involves many confounding factors. Des(1-3)IGF-1's short half-life and localized effects may mitigate this concern compared to systemic, long-acting IGF-1 elevation, but no long-term data exist.

Receptor Downregulation: Chronic activation of IGF1R through supraphysiological ligand exposure could lead to receptor desensitization or downregulation, potentially diminishing endogenous IGF-1 sensitivity. The peptide's short half-life may reduce this risk compared to sustained receptor activation from longer-acting analogs.

Cardiovascular Effects: IGF-1 affects cardiac tissue, where IGF1R is expressed on cardiomyocytes. Research generally indicates IGF-1 has cardioprotective effects, but excessive activation could theoretically promote cardiac hypertrophy. Clinical relevance in the context of Des(1-3)IGF-1 use remains uncertain.

Edema and Joint Pain: Native IGF-1 therapy sometimes causes fluid retention and arthralgia. Whether Des(1-3)IGF-1 produces similar effects is unknown, though its short duration might reduce the likelihood of fluid accumulation.

Research Findings:

Animal studies generally report good tolerability of Des(1-3)IGF-1 at research doses. Studies in rats following gut resection found that Des(1-3)IGF-1-treated animals stabilized better and gained weight without reported adverse effects. Research in growth hormone-deficient mice demonstrated enhanced growth without obvious toxicity.

However, these studies typically involve short-term administration in specific disease models. They provide limited information about safety in healthy subjects or with chronic use.

Contraindications and Precautions:

Based on IGF-1 pharmacology, Des(1-3)IGF-1 would theoretically be contraindicated in:

  • Active malignancy or history of cancer (due to proliferative effects)
  • Diabetic retinopathy or other proliferative retinopathy (IGF-1 has complex effects on retinal neovascularization)
  • Children and adolescents (potential effects on growth plate closure and development)

Precautions would apply for individuals with:

  • Diabetes or impaired glucose regulation (hypoglycemia risk)
  • Cardiovascular disease (theoretical concerns about cardiac effects)
  • Renal or hepatic impairment (altered peptide clearance)

Quality and Contamination Risks:

An important safety consideration involves the source and purity of research-grade peptides. Des(1-3)IGF-1 is not an FDA-approved pharmaceutical product. Peptides obtained through research chemical suppliers may vary in purity, contain contaminants, or be mislabeled. These quality control issues represent tangible risks separate from the peptide's inherent pharmacology.

Regulatory Status and Prohibited Use:

Des(1-3)IGF-1 is explicitly prohibited by the World Anti-Doping Agency under the category of peptide hormones and growth factors. Detection methods exist, and the peptide has been identified in anti-doping analyses, confirming its use in athletic contexts. This prohibited status reflects concerns about performance enhancement and safety in competitive sports.

IGF-1 DES occupies a regulatory gray zone in most jurisdictions. The peptide is neither an approved pharmaceutical nor explicitly scheduled as a controlled substance in most countries, but its legal status for various uses varies considerably.

United States:

In the U.S., Des(1-3)IGF-1 is not approved by the Food and Drug Administration for any medical indication. It is not scheduled under the Controlled Substances Act. However, several regulatory frameworks affect its status:

The Federal Food, Drug, and Cosmetic Act prohibits the sale or distribution of unapproved drugs for human consumption. Suppliers offering Des(1-3)IGF-1 typically label it "for research purposes only" to avoid classification as an unapproved drug. This labeling creates ambiguous legal status — the peptide can be purchased for laboratory research but not legally sold or marketed for human use.

The peptide does not appear on the DEA's list of controlled anabolic steroids, despite its growth-promoting properties. This distinguishes it from synthetic steroids but does not convey approval for human use.

Anti-Doping Regulations:

The World Anti-Doping Agency (WADA) explicitly prohibits Des(1-3)IGF-1 under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the Prohibited List. This prohibition applies at all times — both in-competition and out-of-competition. Athletes subject to WADA rules, including NCAA athletes and participants in Olympic sports, face sanctions if Des(1-3)IGF-1 is detected.

Detection methods using immunopurification and high-resolution mass spectrometry have been developed specifically for LongR3-IGF-1, Des(1-3)-IGF-1, and R3-IGF-1 for anti-doping purposes. These methods can identify IGF-1 analogs in biological samples, making detection feasible in drug testing programs.

International Status:

Regulatory status varies by country. In Australia, IGF-1 and analogs are classified as Schedule 4 (Prescription Only Medicine), making unauthorized possession illegal. Many European countries regulate peptides under medicines legislation, prohibiting sale for human consumption without marketing authorization.

Some jurisdictions with less developed pharmaceutical regulations may have no specific controls on research peptides, creating variable legal landscapes globally.

Research and Laboratory Use:

Des(1-3)IGF-1 is available from biochemical suppliers for legitimate research purposes. Universities, pharmaceutical companies, and research institutions can obtain the peptide for in vitro studies, animal research, and mechanistic investigations. This research use is generally legal and appropriate within institutional review and safety frameworks.

Clinical Use:

No jurisdiction has approved Des(1-3)IGF-1 for clinical use. The peptide has not undergone the safety and efficacy trials required for pharmaceutical approval. Off-label prescribing is not possible because the peptide is not an approved medication in any indication.

Compounding and Manufacturing:

Some peptide manufacturers produce Des(1-3)IGF-1 as a research chemical. Quality, purity, and identity verification vary among suppliers. The lack of pharmaceutical manufacturing standards means peptides obtained through these channels may not meet medical-grade specifications.

Frequently Asked Questions

What is the difference between IGF-1 and IGF-1 DES?

IGF-1 DES is a truncated form of insulin-like growth factor-1 missing the first three amino acids (glycine-proline-glutamic acid) from its N-terminus. This makes it a 67-amino acid peptide compared to 70 for native IGF-1. The structural difference dramatically reduces binding to IGF binding proteins (retaining only about 1% of native IGF-1's binding affinity) while maintaining normal receptor binding. As a result, IGF-1 DES is approximately 10 times more potent than native IGF-1 at stimulating growth, but it has a much shorter half-life (20-30 minutes versus several hours).

How does IGF-1 DES compare to IGF-1 LR3?

The primary differences lie in structure and half-life. IGF-1 DES is truncated (missing N-terminal amino acids) while IGF-1 LR3 is extended (with additional N-terminal amino acids). IGF-1 DES has a half-life of 20-30 minutes, making it highly localized and short-acting. IGF-1 LR3 has a half-life of 20-30 hours, producing systemic, long-lasting effects throughout the body. IGF-1 DES is suited for targeted, local tissue applications with rapid onset and offset. IGF-1 LR3 excels at whole-body anabolic effects with sustained duration.

Is IGF-1 DES legal?

IGF-1 DES is not approved by the FDA or other regulatory authorities for human use. It is legal to purchase as a research chemical in many jurisdictions, but it cannot be legally sold or marketed for human consumption. It is explicitly prohibited in competitive sports by the World Anti-Doping Agency. Athletes tested positive for Des(1-3)IGF-1 face sanctions. Legal status varies by country, with some nations regulating it as a prescription-only medicine.

What are the potential side effects of IGF-1 DES?

Safety data in humans is extremely limited because the peptide has not undergone clinical trials. Theoretical concerns based on IGF-1 pharmacology include hypoglycemia (low blood sugar), proliferative effects (potentially concerning in cancer contexts), receptor downregulation with chronic use, and cardiovascular effects. Animal research has generally shown good tolerability at research doses, but long-term safety data does not exist. The short half-life may reduce some risks compared to longer-acting IGF-1 analogs, as effects resolve quickly.

How is IGF-1 DES administered in research?

In animal research, Des(1-3)IGF-1 has been administered through various routes including intraperitoneal injection, subcutaneous injection, and direct tissue injection. The peptide's short half-life and high potency make it particularly suited for site-specific administration when localized effects are desired. Research examining systemic effects has used intraperitoneal or subcutaneous routes. Human administration protocols have not been established through clinical research.

Does IGF-1 DES occur naturally in the body?

Yes, Des(1-3)IGF-1 is a naturally occurring peptide. It has been isolated from bovine colostrum, human brain tissue, and porcine uterus. Research has identified acid proteases in serum that can enzymatically convert native IGF-1 to Des(1-3)IGF-1 by cleaving the N-terminal tripeptide. This enzymatic conversion may represent a physiological mechanism for increasing local IGF-1 bioavailability in specific tissues. The peptide's natural occurrence suggests it serves biological functions, though its precise physiological roles are not fully characterized.

What is the half-life of IGF-1 DES?

Des(1-3)IGF-1 has a circulating half-life of approximately 20-30 minutes. This short duration results from its dramatically reduced binding to IGF binding proteins, which normally stabilize and extend IGF-1's circulating time. Without binding protein protection, the peptide is rapidly cleared from circulation. This brief half-life distinguishes Des(1-3)IGF-1 from native IGF-1 (half-life of several hours) and long-acting analogs like IGF-1 LR3 (half-life of 20-30 hours).

Can IGF-1 DES be detected in drug tests?

Yes. Anti-doping laboratories have developed detection methods for Des(1-3)IGF-1 using immunopurification and high-resolution mass spectrometry. These methods can identify the peptide and distinguish it from native IGF-1 and other analogs. The World Anti-Doping Agency prohibits Des(1-3)IGF-1, and athletes subject to drug testing should be aware that use can result in positive tests and sanctions. Detection windows depend on the assay sensitivity and the time since administration, but the peptide's short half-life means it clears from circulation relatively quickly.

The Bottom Line

IGF-1 DES (Des(1-3)IGF-1) represents a naturally occurring truncated variant of insulin-like growth factor-1 with unique pharmacological properties that distinguish it from both native IGF-1 and other synthetic analogs. Its structural modification — the absence of three N-terminal amino acids — produces a peptide with dramatically reduced binding to IGF binding proteins while maintaining full receptor binding capacity. This translates to approximately 10-fold greater potency than native IGF-1 in biological systems.

The peptide's extremely short half-life of 20-30 minutes creates a pharmacokinetic profile suited for localized, transient effects rather than systemic, sustained action. This characteristic makes it particularly interesting for research applications emphasizing targeted tissue growth, such as muscle hypertrophy at specific sites or intestinal tissue repair following resection. Animal research demonstrates effectiveness across multiple models, including enhanced growth in growth hormone-deficient mice, improved outcomes in intestinal resection models, and benefits in renal insufficiency.

However, several significant limitations constrain interpretation and application of this research. First, human clinical data is essentially absent. The peptide has not undergone controlled trials establishing safety or efficacy in humans. All available evidence derives from animal models or in vitro systems, making extrapolation to human physiology uncertain. Second, the peptide lacks regulatory approval anywhere in the world. It cannot be legally prescribed or sold for human consumption, existing only in the gray market of research chemicals. Third, quality control issues affect products available through research chemical suppliers, creating additional safety concerns beyond the peptide's inherent pharmacology.

The peptide's prohibited status in competitive sports reflects both performance-enhancing potential and unresolved safety questions. Anti-doping agencies have developed detection methods and documented use in athletic contexts despite prohibitions. Athletes face sanctions if Des(1-3)IGF-1 is identified in drug testing.

From a research perspective, Des(1-3)IGF-1 provides a valuable tool for studying IGF-1 receptor signaling without the confounding effects of binding protein sequestration. Its natural occurrence in human tissues suggests physiological relevance, and enzymatic mechanisms exist for generating the truncated variant from native IGF-1. These characteristics make it scientifically interesting beyond its potential applications.

Comparison with IGF-1 LR3 illustrates how different structural modifications produce distinct pharmacokinetic profiles suited to different research questions. Neither analog has advanced to pharmaceutical development, but they serve complementary research purposes — Des(1-3)IGF-1 for localized, short-acting effects, and IGF-1 LR3 for systemic, sustained action.

The current evidence suggests Des(1-3)IGF-1 has biological activity consistent with enhanced IGF-1 signaling, particularly in promoting anabolic processes in muscle and gastrointestinal tissue. Whether these effects translate to therapeutic benefit in human disease, and whether such benefits would outweigh risks, remains unknown without clinical investigation. The peptide's research applications continue to provide insights into IGF-1 biology and localized growth factor signaling.

Disclaimer: This article is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. IGF-1 DES is not approved for human use by the FDA or any regulatory authority. It is prohibited in competitive sports. Always consult qualified healthcare professionals before considering any peptide therapy or research chemical. PeptideJournal.org does not sell peptides or endorse their use outside legitimate research contexts.

References

  1. Francis GL, et al. "Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I." International Journal of Biochemistry & Cell Biology. 1996. PubMed

  2. Tomas FM, et al. "IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection." American Journal of Physiology-Endocrinology and Metabolism. 1991. PubMed

  3. Ballard FJ, et al. "Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice." Endocrinology. 1989. PubMed

  4. Zhu M, et al. "Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes." Drug Testing and Analysis. 2021. PubMed

  5. Wallis M. "Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action." Journal of Endocrinology. 1995. PubMed

  6. Hoyt EC, et al. "Des(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats." Investigative Ophthalmology & Visual Science. 2003. PubMed

  7. Florini JR, et al. "Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy." Cells. 2020. PMC

  8. Hawkes CP, et al. "The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticity." Neuroscience. 2016. PubMed

  9. Dyer AH, et al. "IGF-1 and Neuroinflammation." Frontiers in Aging Neuroscience. 2017. Frontiers

  10. Firth SM, et al. "IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?" Frontiers in Endocrinology. 2018. PMC

  11. Yamada PM, Lee KW. "Perspectives in mammalian IGFBP-3 biology: local vs. systemic action." American Journal of Physiology - Cell Physiology. 2009. PubMed

  12. Swolverine. "IGF-1 LR3 vs IGF-1 DES: Which Peptide Is Best for Muscle Growth and Recovery." 2024. Swolverine Blog